Literature DB >> 14981634

Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy.

Todd E Pesavento1, William H Bay, Garima Agarwal, Raul A Hernandez, Lee A Hebert.   

Abstract

We report 4 consecutive adult patients with steroid-responsive frequently relapsing minimal change disease (MCD) who continued to experience relapse after 1 to 4 courses of cyclophosphamide therapy. Each patient then was administered mycophenolate mofetil (MMF) and prednisone in tapering doses. This therapy was followed by sustained remission and is being well tolerated. MMF is promising therapy in frequently relapsing MCD, even in those with disease that continued to relapse after cyclophosphamide therapy. A controlled clinical trial of MMF therapy in this disorder is warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981634     DOI: 10.1053/j.ajkd.2003.11.015

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

1.  American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.

Authors:  Fernando C Fervenza; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

Review 2.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

3.  Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; T Kahn; J Fahnert
Journal:  Clin Exp Immunol       Date:  2015-11-26       Impact factor: 4.330

4.  A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus.

Authors:  Young Hoon Hong; Dae Young Yun; Yong Wook Jung; Myung Jin Oh; Hyun Je Kim; Choong Ki Lee
Journal:  Korean J Intern Med       Date:  2011-11-28       Impact factor: 2.884

Review 5.  Minimal Change Disease.

Authors:  Marina Vivarelli; Laura Massella; Barbara Ruggiero; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.